Orange Health Labs

orangehealth.in →

-77%

est. 2Y upside i

HealthcareSeries A

India's Fastest Diagnostics Service

Rank

#3096

Sector

Laboratory Services (Healthcare)

Est. Liquidity

~3Y

Data Quality

Data: High

Orange Health Labs presents a high-risk, moderate-upside equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (25%)+150%

Orange Health Labs successfully leverages its speed and convenience moat, expands its omnichannel presence to 30+ centers, and sees strong adoption of Orange One and other preventive healthcare offerings, driving revenue to $60M+ by 2028 and justifying a $375M+ valuation at 6x revenue, well above the current $150M.

Base (30%)+30%

The company maintains its strong growth trajectory in key metro areas but faces increasing pricing pressure from incumbents, leading to moderate market share gains. Revenue reaches $30M by 2028, resulting in a $195M valuation, a modest increase from the current $150M.

Bear (45%)-50%

Dominant incumbents aggressively expand their home collection services and pricing, eroding Orange Health Labs' competitive edge. The company struggles to achieve consistent company-wide profitability, leading to slower growth and a down round to a $75M valuation, significantly impacting common stock value given the $47M in liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Investors hold $47M in liquidation preferences, which is 31.3% of the estimated $150M current valuation.

Dilution Risk

high

As a Series B company targeting overall profitability by early 2028, Orange Health Labs will likely require at least one more significant funding round, leading to further dilution for existing equity holders.

Secondary Liquidity

limited

While the company had a $1M equity buyback program in 2022, active secondary markets for early-stage private companies are generally limited.

Questions to Ask at the Interview

Strategic questions based on Orange Health Labs's data — designed to show you've done your homework.

  • 1

    “Given the strong competition from established players like Dr Lal PathLabs and Metropolis Healthcare who are expanding their home collection services, how does Orange Health Labs plan to sustain its competitive moat and pricing power in the long term?”

  • 2

    “With a current run-rate of ~$12M and 100% YoY growth, what are the key strategic initiatives and milestones for the next 18-24 months to achieve company-wide profitability by early 2028 and scale revenue significantly?”

  • 3

    “Considering the Series B funding and the target for overall profitability by early 2028, what is the company's anticipated timeline for a liquidity event (IPO or acquisition), and how is employee equity structured to ensure meaningful returns for common shareholders given the preference stack?”

Community

Valuation Sentiment

Our model estimates -77% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.